Quantcast
Last updated on April 21, 2014 at 9:11 EDT

Topiramate Exposure and Fetal Outcomes in Migraine Patients to Be Presented at the 136th ANA Annual Meeting

September 26, 2011

MOUNTAIN VIEW, Calif., Sept. 26, 2011 /PRNewswire/ — VIVUS, Inc. (NASDAQ: VVUS) today announced that a poster authored by Dr. Mark W. Green, Director of the Center for Headache and Pain Medicine and Professor of Neurology and Anesthesiology at the Mount Sinai School of Medicine, will be presented at the American Neurological Association (ANA) Meeting in San Diego, CA. In addition to the topiramate exposure data previously reported, the results will include the rate of major congenital malformations (MCMs) and oral clefts (OCs) in two new control groups, a migraine without epilepsy group, and a sub-group of patients exposed to acute- and preventive migraine drugs, or APMD, during pregnancy.


    Details of the presentation:
    ----------------------------

    Date:      Tuesday, September 27, 2011

    Location:  Manchester Grand Hyatt, San Diego, CA

                "Retrospective Analysis of Major Congenital Malformations and
    Title:      Oral Clefts  Associated With In Utero Topiramate Exposure"

                Mark W. Green, MD, Mount Sinai School of Medicine, New York,
                NY, USA; Arun Bhattacharyya, PhD, Wolters Kluwer Pharma
    Authors:    Solutions, Yardley, Pennsylvania, USA

    Poster #:  T1623

                6:00-7:00pm local time (poster will be displayed from 10:00am
    Time:       - 7:00pm on Tuesday)

Copies of the poster are available on our website at www.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company’s lead investigational product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial QNEXA NDA on October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS has submitted an NDA for avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.


    CONTACT:
    --------

                          Investor
    VIVUS, Inc.           Relations:      The Trout Group
    Timothy E. Morris                     Brian Korb
    Chief Financial
     Officer                              bkorb@troutgroup.com
    650-934-5200                          646-378-2923

SOURCE VIVUS, Inc.


Source: PR Newswire